Drug could double survival in rare stem cell transplant complication
NCT ID NCT07707687
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests the drug eculizumab in adults who develop a severe blood clotting disorder called high-risk transplant-associated thrombotic microangiopathy (TA-TMA) after a stem cell transplant. The condition can cause multiple organ failure and has a poor outlook. The study aims to see if eculizumab can improve survival at 6 months compared to historical outcomes. Participants receive weight-based doses over up to 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eculizumab, a complement C5 inhibitor
- What this could lead to
- If successful, this could offer a targeted treatment for a life-threatening complication after stem cell transplants, potentially doubling survival rates.
- What could go wrong
- This is a small, early-phase study with only 24 participants and no control group, so results may not be definitive. Eculizumab also carries risks like increased susceptibility to infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinhua Central Hospital
RECRUITINGJinhua, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated People's Hospital of Ningbo University
RECRUITINGNingbo, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Ningbo University
RECRUITINGNingbo, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine.
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••